Research & Development
Dr. Reddy's Laboratories Launches Capecitabine Tablets, USP in the US Market
19 February 2021 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY) has launched Capecitabine Tablets, USP a therapeutic equivalent generic version of Xeloda (capecitabine) Tablets approved by the US Food and Drug Administration (USFDA), the company said.

The Xeloda brand and generic had US sales of approximately USD 90m MAT for the most recent twelve months ending in October 2020 according to IQVIA Health.

Dr. Reddy's Capecitabine Tablets, USP are available in 150 mg and 500 mg strengths in bottle count sizes of 60 and 120, respectively.

Dr. Reddy's Laboratories is an integrated pharmaceutical company. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Dr. Reddy's major markets include USA, India, Russia and CIS countries, and Europe.